Prognostic Factors in Advanced Ovarian Cancer
Author Information
Author(s): Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, Harbeck N, Späthe K, Dettmar P, Höfler H, Jänicke F, Schmitt M, Graeff H
Primary Institution: Frauenklinik der Technischen Universität München, Klinikum rechts der Isar, München, Germany
Hypothesis
The study evaluates the prognostic impact of urokinase plasminogen activator (uPA) and its inhibitor PAI-1 on overall survival in patients with advanced ovarian cancer stage FIGO IIIc.
Conclusion
Both residual tumour mass and PAI-1 are strong, statistically independent prognostic factors for overall survival in patients with advanced ovarian cancer.
Supporting Evidence
- uPA and PAI-1 were determined by ELISA in primary tumour tissue extracts of 86 ovarian cancer patients.
- Univariate analysis showed that uPA and PAI-1 were of prognostic significance for overall survival.
- In multivariate analysis, PAI-1 and residual tumour mass were strong, statistically independent prognostic parameters.
Takeaway
This study found that certain proteins in ovarian cancer can help doctors predict how long patients might live, which can help in planning their treatment.
Methodology
The study used ELISA to determine uPA and PAI-1 levels in tumor tissue from patients and performed univariate and multivariate analyses using the Cox proportional hazard model.
Participant Demographics
Patients with advanced ovarian cancer stage FIGO IIIc.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website